Risks tied to this specific entity.
No issues detected across 7 sources
No issues detected across 1 source
Lonza Group's divestiture of its Personalized Medicine Business to Octane Medical Group presents supply chain and operational continuity risks requiring monitoring.
Lonza Group's divestiture of its Personalized Medicine Business to Octane Medical Group presents high supply chain risk due to potential operational disruption, customer continuity concerns, and transition management complexities.
Lonza warns that major pharmaceutical companies may postpone outsourcing decisions due to competing U.S. manufacturing investments, creating potential near-term revenue uncertainty for the CDMO.
pharmaceuticalonline.com: Lonza Expands HPAPI Capacity In Visp Further Supporting I...; manilatimes.net: Stipple Bio Enters Multi - Target License Agreement with ...; lavozdegalicia.es: El nuevo director de Lonza traslada a la Xunta sus proyec...
GDELTNo issues detected across 2 sources
Top origins: Switzerland, Belgium, Germany. Period: 2023-07-01 to 2026-07-01
ImportYeti (US Customs)No issues detected across 1 source
No issues detected across 1 source
Risks tied to the location of this facility.
Political stability: 1.07, Rule of law: 1.76, Corruption control: 2.02
World Bank WGI 2023No issues detected across 2 sources
No issues detected across 3 sources